Banner Banner


In the year 2000, Dr. Ilan Morad had an idea as to how to create what can be described as a functional Phage Display. With this idea he applied for the ITEK incubator in the Weizmann Science Park. Six years later, AEBi was able to prove that the novel technology, titled ‘SoAP’, really works.

Within the Phage Display family, and unlike other members of this family of technologies, AEBi’s platform provides functional leads to very difficult targets (functional leads – agonist, antagonist, inhibitor, etc.), not merely those that best bind with the target.

  • SoAP allows AEBi to develop drugs to many illnesses, among them cancer, and is expected to transform the drug discovery R&D phase by significantly reducing the attrition rate of new drug candidates
  • SoAP technology generates very specific lead compounds with greater functionality and improved pharmacological properties.
  • The sole external requirement in the screening process is a Defined Target (usually an illness-related protein).

SoAP's Advantages over existing technologies


Success Rate

Rapid isolation and identification of lead compounds. Our solution will hit and activate or deactivate any protein-based target.


Isolation of lead compounds from vast libraries. Dramatically expands the range of targets, to include even the most challenging ones.


Selection conditions can be alerted to isolate lead compounds with particular functional characteristics (agonist, antagonist, inhibitors, etc.). Unparalleled high "signal to noise" ratio.

Technical - what do we do differently?

AEBi Platform features: Each round has both affinity and efficacy properties.
Banner Banner

About Us

In the year 2000, Dr. Ilan Morad had an idea as to how to create what can be described as a functional Phage Display. With this idea he applied for the ITEK incubator in the Weizmann Science Park in Israel. Six years later, AEBi was able to prove that the novel technology, titled 'SoAP' (IP protected), really works. The platform is very flexible, exploiting combinatorial biology to discover new and better lead compounds to disease targets. The major advantage is that it can be used not only to find binders to known targets, but to select the best functional molecules among them. AEBi has been managed since then based on the idea that the ability to manipulate and design peptides has vastly superior advantages to many, existing and trajectory technologies of drug development. This idea is valid today as well.



Founder and CEO



Chairman of the Board



Chief Science Officer



Assistant to the chairman



The Richard Feynman principle

Focusing on the science & technology on the critical path to proof of concept

The Clayton Christensen principle

Don't water down the solution in order to generate Investor\Pharma\Media traction

The Capecchi principle

Research & Development of a comprehensive fundamental idea

Transparent Management practices

Private investors with a long term outlook, adhering in advance to the Company's goals and methods - The practical approach that worked for us.

We do not engage in Financial wizardry - No Debt, No Bank Credit, No Loans.

Our team are research scientists (Ph.D.) and are not attending Dr.

We are working now for the 20th year entering our 21th year of R&D effort (in June 2022).

We don’t have a Clinique and we can not advise nor refer to any specific case.

We initially intend to target: lung, colon, head & neck cancers.

The treatment, in any case, has to be individually adapted to the patient.

We are a small team and have an influx of e-mail.

We try to answer at least initial emails but can not promise it.

This website may contain certain statements, estimations, projections, assessments and other information with respect to the anticipated future performance of the Company and/or its market and involve risks and uncertainties. Actual results or future business decisions of the Company may differ materially from any expectations, projections or predictions made or implicated in statements made in this website. While the Company believes that the information contained herein is accurate, it expressly disclaims any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this website or any other communication transmitted or made available herein. Any prospective website user acknowledges his/her responsibility to perform a due diligence review prior to consummating a transaction with the Company. Included in this website are certain declarations by the Company with respect to its anticipated future performance. These declarations are based on estimates and assumptions by the Company that are subject to economic and competitive uncertainties beyond the control of the Company. The Company does not provide representation or warranty with regard to the declarations and there can be no assurance that the future results will be realized or that actual results will not be significantly different from those projected. The Company is not obligated to update or revise any future declarations. The Company and its respective affiliates, directors, officers, employees, consultants and representatives expressly disclaim any and all liability relating to or resulting from the utilization of any information contented in this website. The Company does not have any obligation to provide with access to additional information.